Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial - Concepedia

Concepedia

Publication | Open Access

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial

DOI Full Paper Access

121

Citations

25

References

2012

Year

Isabelle Demeestere, Pauline Brice, Fedro A. Peccatori, Alain Kentos, Isabelle Gaillard, Pierre Zachée, Olivier Casasnovas, Éric Van Den Neste, Julie Dechène, Viviane De Maertelaer,

Journal of Clinical Oncology

Abstract

Approximately 20% of patients in both groups exhibited POF after 1 year of follow-up. Triptorelin was not associated with a significant decreased risk of POF in young patients treated for lymphoma but may provide protection of the ovarian reserve.

References

	Year	Citations

Page 1